Angst, J, Sellaro, R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry
2000; 48: 445–57.
Post, RM, Rubinow, DR, Ballenger, JC. Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry
1986; 149: 191–201.
Oepen, G, Baldessarini, RJ, Salvatore, P, Slater, E. On the periodicity of manic-depressive insanity, by Eliot Slater (1938): translated excerpts and commentary. J Affect Disord
2004; 78: 1–9.
Berk, M, Berk, L, Dodd, S, Cotton, S, Macneil, C, Daglas, R, et al. Stage managing bipolar disorder. Bipolar Disord
2014; 16: 471–7.
Franchini, L, Zanardi, R, Smeraldi, E, Gasperini, M. Early onset of lithium prophylaxis as a predictor of good long-term outcome. Eur Arch Psychiatry Clin Neurosci
1999; 249: 227–30.
Kessing, LV, Vradi, E, Andersen, PK. Starting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry
2014; 205: 214–20.
Maj, M, Pirozzi, R, Magliano, L. Nonresponse to reinstituted lithium prophylaxis in previously responsive bipolar patients: prevalence and predictors. Am J Psychiatry
1995; 152: 1810–1.
Baldessarini, RJ, Tondo, L, Baethge, CJ, Lepri, B, Bratti, IM. Effects of treatment latency on response to maintenance treatment in manic-depressive disorders. Bipolar Disord
2007; 9: 386–93.
Berk, M, Dodd, S. Recent developments in the treatment of bipolar disorders. Expert Opin Investig Drugs
2003; 12: 1621–32.
Bowden, CL, Grunze, H, Mullen, J, Brecher, M, Paulsson, B, Jones, M, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry
2005; 66: 111–21.
McIntyre, RS, Brecher, M, Paulsson, B, Huizar, K, Mullen, J. Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol
2005; 15: 573–85.
Vieta, E, Mullen, J, Brecher, M, Paulsson, B, Jones, M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin
2005; 21: 923–34.
Calabrese, JR, Keck, PE Jr, Macfadden, W, Minkwitz, M, Ketter, TA, Weisler, RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry
2005; 162: 1351–60.
Young, AH, McElroy, SL, Bauer, M, Philips, N, Chang, W, Olausson, B, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry
2010; 71: 150–62.
Keck, PE, Orsulak, PJ, Cutler, AJ, Sanchez, R, Torbeyns, A, Marcus, RN, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord
2009; 112: 36–49.
Tohen, M, Ketter, TA, Zarate, CA, Suppes, T, Frye, M, Altshuler, L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry
2003; 160: 1263–71.
Bowden, CL. Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. J Clin Psychiatry
2005; 66 (suppl 3): 12–9.
Conus, P, Berk, M, Cotton, SM, Kader, L, Macneil, C, Hasty, MK, et al. Olanzapine or chlorpromazine plus lithium in first episode psychotic mania: an 8-week randomised controlled trial. Eur Psychiatry
2015; 30: 975–82.
First, MB, Spitzer, , Robert, L, Miriam, Gibbon, and Williams, , Janet, BW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). Biometrics Research, New York State Psychiatric Institute, 2002.
Young, RC, Biggs, JT, Ziegler, VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry
1978; 133: 429–35.
Overall, JE, Gorham, DR. The Brief Psychiatric Rating Scale. Psychol Rep
1962; 10: 799–812.
Berk, M, Malhi, GS, Cahill, C, Carman, AC, Hadzi-Pavlovic, D, Hawkins, MT, et al. The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord
2007; 9: 571–9.
Montgomery, SA, Åsberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry
1979; 134: 382–9.
Spearing, M, Post, RM, Leverich, GS, Brandt, D, Nolen, W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res
1997; 73: 159–71.
Jones, SH, Thornicroft, G, Coffey, M, Dunn, G. A brief mental health outcome scale – reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry
1995; 166: 654–9.
Morosini, PL, Magliano, L, Brambilla, L, Ugolini, S, Pioli, R. Development, reliability and acceptability of a new version of the DSM-IV Social Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand
2000; 101: 323–9.
Heinrichs, DW, Hanlon, TE, Carpenter, WT. The Quality of Life Scale: an instrument for rating schizophrenic deficit syndrome. Schizophrenia Bull
1984; 10: 388–98.
Tohen, M, Hennen, J, Zarate, CM Jr, Baldessarini, RJ, Strakowski, SM, Stoll, AL, et al. Two-year syndromal and functional recovery in 219 cases of first episode major affective disorder with psychotic features. Am J Psychiatry
2000; 157: 220–8.
Mallinckrodt, C, Watkin, J, Molenberghs, G, Carroll, R. Choice of the primary analysis in longitudinal clinical trials. Pharm Stat
2004; 3: 161–9.
Gueorgieva, R, Krystal, JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry
2004; 61: 310–7.
Rothman, KJ. No adjustments are needed for multiple comparisons. Epidemiology
1990; 1: 43–6.
Yildiz, A, Vieta, E, Leucht, S, Baldessarini, RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology
2011; 36: 375–89.
Nierenberg, AA, Sylvia, LG, Leon, AC, Reilly-Harrington, NA, Shesler, LW, McElroy, SL, et al. Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder (Bipolar CHOICE): a pragmatic trial of complex treatment for a complex disorder. Clin Trials
2014; 11: 114–27.
Weisler, RH, Nolen, WA, Neijber, A, Hellqvist, A, Paulsson, B, Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry
2011; 72: 1452–64.
Suppes, T, Vieta, E, Gustafsson, U, Ekholm, B. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Depress Anxiety
2013; 30: 1089–98.
Hartong, EG, Moleman, P, Hoogduin, CA, Broekman, TG, Nolen, WA, LitCar, G. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry
2003; 64: 144–51.
Berk, M, Kapczinski, F, Andreazza, AC, Dean, OM, Giorlando, F, Maes, M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev
2011; 35: 804–17.
Passos, IC, Mwangi, B, Vieta, E, Berk, M, Kapczinski, F. Areas of controversy in neuroprogression in bipolar disorder. Acta Psychiatr Scand
2016; 134: 91–103.
Calabrese, JR, Vieta, E, El-Mallakh, R, Findling, RL, Youngstrom, EA, Elhaj, O, et al. Mood state at study entry as predictor of the polarity of relapse in bipolar disorder. Biol Psychiatry
2004; 56: 957–63.
Vieta, E, Berk, M, Wang, W, Colom, F, Tohen, M, Baldessarini, RJ. Predominant previous polarity as an outcome predictor in a controlled treatment trial for depression in bipolar I disorder patients. J Affect Disord
2009; 119: 22–7.
Schalkwijk, S, Undurraga, J, Tondo, L, Baldessarini, RJ. Declining efficacy in controlled trials of antidepressants: effects of placebo dropout. Int J Neuropsychopharmacol
2014; 17: 1343–52.
Grande, I, Berk, M, Birmaher, B, Vieta, E. Bipolar disorder. Lancet
2016; 387: 1561–72.